Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Progress Against Cancer
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Researchers are exploring new options for kidney cancer treatments.
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug discovery.
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts on precision medicine.
January is Cervical Cancer Awareness Month. Here's the latest on prevention, screening, and treatment.
Metastatic breast cancer remains incurable, but researchers’ understanding of the molecular features of the disease is leading to additional treatments.
Researchers are looking at ways to lessen and even prevent the debilitating chemotherapy-related side effect that causes numbness and pain in the hands and feet.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More